NCT00001357View on ClinicalTrials.gov

Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 1993

Study Completion Date

April 30, 2002

Conditions
HIV Infection
Interventions
DRUG

Interleukin-2

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001357 - Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients | Biotech Hunter | Biotech Hunter